Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03960840 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL

Start date: June 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).

NCT ID: NCT03958916 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL

Start date: May 5, 2017
Phase:
Study type: Observational [Patient Registry]

The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.

NCT ID: NCT03952572 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Start date: May 10, 2019
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for newly diagnosed peripheral T-cell lymphoma (PTCL).

NCT ID: NCT03943901 Recruiting - Cancer Clinical Trials

Split-Dose R-CHOP for Older Adults With DLBCL

Start date: February 17, 2021
Phase: Phase 2
Study type: Interventional

This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).

NCT ID: NCT03938987 Recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

ACIT001/EXC002
Start date: March 3, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).

NCT ID: NCT03936153 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Start date: January 20, 2020
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

NCT ID: NCT03934567 Recruiting - Clinical trials for Lymphoma, Follicular

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: April 22, 2020
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)

NCT ID: NCT03934372 Recruiting - Lymphoma Clinical Trials

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Start date: January 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

NCT ID: NCT03932955 Recruiting - Lymphoma Clinical Trials

MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT03932279 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Characterization of the Microbiome in Cutaneous T Cell Lymphoma

Start date: January 30, 2019
Phase:
Study type: Observational

Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.